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Abdominal aortic aneurysm (AAA) is distinctly uncommon in infants and children, and usually results from infection,
iatrogenic trauma, vasculitis, connective tissue disorder, or tuberous sclerosis. Congenital “primary” neonatal AAA is
exceedingly rare. The few reported cases of repair of congenital AAA describe use of synthetic graft material or
aneurysmorrhaphy. We report the first successful treatment of a known 6 cm congenital infrarenal AAA repaired with a
5 mm cryopreserved allograft in a 4-month-old infant girl. The graft was pretreated with an antigen reduction process
(SynerGraft), which preliminary studies suggest may inhibit allograft degeneration. The postoperative course was
unremarkable. Lower extremity pulses and results of duplex ultrasound flow studies remained excellent at 14-month
follow-up. Panel reactive antibodies against class I alloantigens remain negative. The use of an antigen-reduced allograft
provides an acceptable conduit, which potentially may decrease allograft degeneration and relative graft stenosis
associated with growth of the child, but requires follow-up. (J Vasc Surg 2003;38:190-3.)
Aneurysm of the abdominal aorta in neonates, infants,
and children is uncommon but significant. Acquired or
secondary causes are more frequently noted, with only rare
published reports of true congenital infrarenal aortic aneu-
rysm.
CASE REPORT
The patient was a phenotypically normal infant girl of a
20-year-old gravida 2, para 1 mother. There was no family history
of connective tissue disorders or aneurysmal disease. There was no
history of prenatal amniocentesis. Uncomplicated vaginal delivery
occurred at 39 weeks of gestation. Apgar scores were 9 and 10.
Birth weight was 3.38 kg. Bilious vomiting occurred on day 1 of
life. Physical examination revealed a large abdominal mass, but no
skin or muscular stigmata of connective tissue disorder. Subse-
quent abdominal ultrasound scans obtained for evaluation of the
vomiting revealed a “cystic appearing 6 cm right lower quadrant
mass.” An echocardiogram revealed normal cardiac valvular anat-
omy. No evidence of coarctation of the thoracic aorta was present.
An initial diagnosis of an ovarian versus mesenteric cyst was made.
Subsequently, the neonatal period was uncomplicated. She fed
well, gained weight appropriately, and had no further bilious
vomiting. There was no history of umbilical artery catheterization.
At 3 weeks of age, the patient underwent exploratory laparotomy,
and the mass was confirmed to be an abdominal aortic aneurysm.
Definitive repair was postponed until the infant was 4 months of
age, to allow adequate healing after the laparotomy and to obtain
a suitable allograft. A preoperative magnetic resonance arteriogram
revealed the aneurysm to be 1 cm below the renal bifurcation and
extending 1 cm proximal to the iliac bifurcation (Fig 1). No other
arterial abnormalities were identified in the chest, abdomen, or
pelvis at magnetic resonance arteriography. There was no mid-
aortic stenosis proximal to the aneurysm, and no thrombus was
identified in the aneurysm. The aorta was explored through the
previous transverse abdominal incision site. The infrarenal aneu-
rysm extended 1 cm proximal to the aortic bifurcation. The aorta
and common iliac arteries were cross-clamped, after which 150 mL
of aneurysmal blood was aspirated into a plasma transfer pack and
reinfused back into the infant. The aneurysm was opened and
repaired with an interposition 5 mm cryopreserved allograft (Fig
2). No thrombus was present in the aneurysm, which had a
uniformly smooth interior and a thin but intact wall. No lumbar
arteries were encountered. The allograft (SynerGraft; CryoLife,
Kennesaw, Ga) was pretreated with an antigen reduction process,
which preliminary studies suggest may inhibit allograft degenera-
tion.1 The postoperative course was unremarkable. The abdominal
incision healed without complication or abnormal scarring. Lower
extremity pulses continued to be excellent at 14-month follow-up.
Duplex ultrasound scans obtained at 1, 4, 8, and 13 months after
surgery showed no flow disturbances in the graft or graft dilation
(49 mm at 15 months). Serial human lymphocyte antigen (HLA)
panel reactive antibodies (PRA) against class I alloantigens have
remained negative.
Histologic evaluation of a portion of the aorta revealed fibro-
muscular dysplasia. There was severe distortion of the normal
aortic architecture, with fibrosis of the media and loss of most of
the medial smooth muscle and elastic fibers. The intima showed
rather myxoid thickening. The internal and external elastic laminae
were absent, and only a few elastic fibers could be found on elastin
stains. Trichrome staining demonstrated pale collagen staining in
the inner layer, moderate collagen in the middle layer, and dense
collagen in the outer layer. Muscle cells were present in the middle
layer, but were fewer in number and were sparse and compressed in
the outer layer. Minimal reticulin was seen at reticulin staining.
The biopsy specimen could not be used to suggest the presence of
any associated genetic syndrome, eg, Marfan syndrome or Ehlers-
Danlos syndrome, or likelihood of involvement of other arteries.
No inflammation was noted in the wall of the aorta. Tissue culture
did not grow any organisms.
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DISCUSSION
True congenital primary aneurysm of the abdominal
aorta is extraordinarily rare. Indeed, this case report docu-
ments only the sixth congenital infrarenal aortic aneurysm
in a living newborn infant since the first report by Howarth2
in 1967. Two of the previously reported infants died before
aneurysm repair2,3; in another infant, nesidioblastosis was
treated with aneurysmorrhaphy4; in 2 infants, repair was
performed with 8 mm and 7 mm polytetrafluoroethylene
(PTFE) tube grafts, respectively5,6; and in 1 infant the
aneurysm was repaired with a PTFE graft, which became
occluded within 6 months (personal communication, Sam
Smith, MD, 2001).
Secondary or acquired aneurysms in infants and chil-
dren occur far more frequently than primary congenital
aneurysms do. Mycotic aneurysms account for half or more
of reported cases of acquired aneurysm, with Staphylococ-
cus the most common organism. Since the advent of um-
bilical artery catheterization in the 1970s, a steady rise in
incidence of mycotic aneurysm has been reported.7-9 Um-
bilical artery catheterization is also associated with trau-
matic aneurysm.
Takayasu arteritis, Kawasaki syndrome, polyarteritis
nodosa, and granulomatous aortitis are among the inflam-
matory vasculitides reported to be associated with aneu-
rysm formation.
Aortic medial degeneration is associated with congen-
ital connective tissue diseases, including Marfan syndrome,
Ehlers-Danlos syndrome, and tuberous sclerosis, and usu-
ally involve the thoracic aorta. These aneurysms are usually
detected in children aged 4 to 15 years.10,11 With the
exception of medical management for some patients with
Takayasu arteritis,12 aortic aneurysm in infants and children
usually is treated with exclusion and replacement with a
synthetic graft material. Our patient’s aneurysmal aorta had
fibromuscular dysplasia. A skin biopsy might be necessary
to exclude such conditions as Ehlers-Danlos syndrome, but
the aortic wall was believed to represent fibromuscular
dysplasia rather than an inflammatory process.
Carrel13 reported successful transplantation of a cryo-
preserved artery in 1908. Forty years later Gross et al14
demonstrated satisfactory preservation and use of allografts
in human beings. From that beginning through the middle
to late 1950s, allograft artery reconstruction was the stan-
dard repair for aneurysmal disease, with fresh, nonpreserved
homografts. Szilagyi et al15 reported significant degenera-
tive changes in implanted arterial homografts, which ush-
ered in a new hesitancy to perform the procedure and
encouraged further use of synthetic materials for aortic
reconstruction. Others corroborated the conclusion of Sz-
ilagyi and colleagues that arterial allografts were poorly
suited for use as vascular substitutes, and clinical use of
arterial allografts was soon abandoned. A follow-up report
14 years later strongly confirmed the findings of gradual
deterioration and degeneration of most aortic, iliac, and
femoral allografts.16
More recently, cryopreserved allografts have been used
for management of problematic mycotic aneurysm and
infected synthetic grafts in adults. Renewed interest, short-
term studies (mostly from Europe), and debate about the
appropriateness of allograft use have logically followed this
resurgence.17-22
Nearly all allografts used throughout the history of
vascular surgery have ultimately degenerated. Further re-
finement of the preparation of allografts to reduce late-term
degeneration has been directed at the cellular components.
Endothelial and fibroblast cells are considered a likely
source of allograft antigenicity, which leads to graft degen-
eration. SynerGraft treatment (CryoLife) is a decellulariza-
tion process, which reduces tissue antigen expression with-
out reducing the strength of the allograft.23 Reduction of
implant cellularity may enable host recellularization of the
matrix, which should favorably affect long-term graft dura-
bility.1 Lack of HLA panel reactive antibodies against class
I alloantigens in this child would seem to support this
hypothesis. The report by Madden et al24 on decellularized
vein allografts for hemodialysis grafts demonstrated no
allosensitization or hindrance with subsequent kidney
transplantation.
Treatment of aneurysm disease in a neonate, infant, or
young child requires additional consideration and concern.
The use of 5 to 10 mm graft material (synthetic or allograft)
for infrarenal aortic aneurysm repair will likely necessitate
future intervention or revision as the child grows. The
average diameter of the adult aorta is 16 to 20 mm. Intu-
itively, this diverging size discrepancy between native aorta
Fig 1. Magnetic resonance image of abdominal aortic aneurysm.
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and graft may impair optimal performance of the growing
child. In addition, the child will be at risk for the potentially
devastating complication of graft infection. To our knowl-
edge, there are no reported studies documenting long-term
follow-up in infants with small (10 mm or less) synthetic or
cryopreserved aortic grafts implanted in any position. We
chose a cryopreserved graft in the hope that its potential for
cellular ingrowth might limit its chances for infection and
the potential for growth with the child. Only careful,
long-term follow-up will answer the question of these
potential properties.
Some previous authors have used cardiopulmonary by-
pass, hypothermia, and blood transfusion when replacing
the abdominal aorta in an infant. We were able to avert use
of these by aspirating the blood in the aneurysm sac and
reinfusing it into the patient. No autologous blood trans-
fusion was necessary.
The cause of this aneurysm is still unclear. While we
have not identified any genetic syndrome in this patient, the
histologic findings are quite nonspecific. Continued fol-
low-up to discover any vascular degeneration in other areas
will be required.
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